IMC Chicago
INDV icon

IMC Chicago’s Indivior Pharmaceuticals INDV Stock Holding History

IMC Chicago’s Portfolio INDV Stock Details INDV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$783K Buy
25,700
+7,500
+41% +$248K ﹤0.01% 3517
2025
Q4 		$653K Buy
+18,200
New +$556K ﹤0.01% 3301

Other funds holding INDV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
OCM
Oaktree Capital Management Los Angeles, California $6.56B AUM 42.97% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

IMC Chicago's INDV Position: Q1 2026 in Review

IMC Chicago reduced its Indivior Pharmaceuticals (INDV) stake by 46% in Q1 2026, selling an estimated $305K and leaving 10,723 shares worth $327K. The position accounts for ﹤0.01% of the portfolio, ranked #4495.

IMC Chicago first reported a position in INDV in Q4 2025 and has held it in 2 quarters since. The position peaked at $716K in Q4 2025. 289 funds tracked by Wall St. Rank hold INDV as of Q1 2026.

  • IMC Chicago held 10,723 shares of Indivior Pharmaceuticals worth $327K as of Q1 2026.
  • IMC Chicago sold 9,229 Indivior Pharmaceuticals shares in Q1 2026, an estimated $305K.
  • Indivior Pharmaceuticals made up ﹤0.01% of IMC Chicago's portfolio in Q1 2026, its #4495 holding.
  • IMC Chicago first reported a position in Indivior Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • IMC Chicago's Indivior Pharmaceuticals position peaked at $716K in Q4 2025.
  • 289 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q1 2026.

Based on IMC Chicago's 13F filing for Q1 2026, filed 5 May 2026.